clinical trial · NCT04311632
A Dose Escalation Study in de Novo Renal Transplantation
Kidney TransplantationTCD601Tacrolimus (TAC)Corticosteroids (CS)Mycophenolate Mofetil (MMF)ATG
brief summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
started
May 26, 2021
primary completion
Oct 3, 2023
completion
Oct 3, 2023
last updated
Feb 27, 2025
official title
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol